Analysis of Anti-Xa Concentrations in Patients on Treatment Dose Enoxaparin: A Retrospective Chart Review

被引:8
|
作者
Levine, Lauren [1 ]
Pallme, Nicole [1 ]
Angelotti, Erik [1 ]
Shiltz, Dane [2 ]
机构
[1] Butler Univ, Coll Pharm & Hlth Sci, Indiana, PA 46208 USA
[2] Indiana Univ Hlth Methodist Hosp, Indianapolis, IN 46202 USA
关键词
Enoxaparin; Anti-Xa; Anticoagulation;
D O I
10.13189/app.2013.010201
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this retrospective chart review was to determine the correlation between full weight-based enoxaparin use and the frequency of anti-Xa concentrations within the defined therapeutic range; to ascertain if anti-Xa monitoring is being appropriately ordered in relation to the timing of enoxaparin dose (after 3 consistent therapeutic doses and 3-5 hours post-dose); to establish if the evidence-based recommended dose adjustment protocol that was studied in the pediatric population was utilized; and if this yielded anti-Xa concentrations within the target range (0.6 -1.1 IU/mL) for an adult population. The data may suggest a lack of correlation between BMI and whether or not the anti-Xa concentration is within the therapeutic range. Further prospective studies are needed to confirm this finding, and to determine the utility of the available dose adjustment nomogram.
引用
收藏
页码:37 / 41
页数:5
相关论文
共 50 条
  • [1] Correlation of Treatment Dose Enoxaparin with Anti-Xa Concentrations in Adult Hemodialysis Inpatients
    Brumley, Paul E.
    Anguelov, Miroslav A.
    Hecht, Jason P.
    Shiltz, Dane
    [J]. ADVANCES IN PHARMACOLOGY AND PHARMACY, 2014, 2 (04) : 59 - 62
  • [2] Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity
    van Oosterom, Nameer
    Winckel, Karl
    Barras, Michael
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 48 (03) : 387 - 393
  • [3] Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity
    Nameer van Oosterom
    Karl Winckel
    Michael Barras
    [J]. Journal of Thrombosis and Thrombolysis, 2019, 48 : 387 - 393
  • [4] IMPACT OF CLOPIDOGREL ON SERUM ANTI-XA LEVELS IN PATIENTS RECEIVING ENOXAPARIN TREATMENT
    Yang, Solomon C.
    Wong, Shing Chiu
    Hwang, Juey-Jen
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [5] Anti-Xa Level Monitoring for Treatment Dose Enoxaparin in Liver/Intestine Transplant Recipients.
    Sullivan, J.
    Jebrock, J.
    Revollo, J.
    Perez, Xi.
    Garcia, J.
    Beduschi, T.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 1111 - 1111
  • [6] EVALUATION OF ANTI-XA LEVEL MONITORING FOR ENOXAPARIN IN TRAUMA PATIENTS
    Chuatrisorn, Ittiporn
    Chui, Sai Ho
    Pajoumand, Mehrnaz
    Stein, Deborah
    [J]. CRITICAL CARE MEDICINE, 2014, 42 (12)
  • [7] SUPRATHERAPEUTIC UNFRACTIONATED HEPARIN ANTI-XA LEVELS DUE TO TREATMENT-DOSE ENOXAPARIN EXPOSURE
    Anthes, Ananth
    Providence, Sarah
    Wilmer, Carrie
    Zhao, Xinhua
    Aspinall, Sherrie
    [J]. CRITICAL CARE MEDICINE, 2022, 50 (01) : 467 - 467
  • [8] ENOXAPARIN PROPHYLAXIS DOSE ADJUSTED BY ANTI-XA TROUGH LEVELS IN CRITICALLY INJURED TRAUMA PATIENTS
    Roth, Jennifer
    Vaughan, Nathan
    Alaidroos, Imaan
    Rainey, Evan Elizabeth
    Roden-Foreman, Jacob
    Powers, Mark
    Garrett, John
    Foreman, Michael
    [J]. CRITICAL CARE MEDICINE, 2018, 46 (01) : 773 - 773
  • [9] Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis
    Lulic-Botica, Mirjana
    Rajpurkar, Madhvi
    Sabo, Cindy
    Tutag-Lehr, Victoria
    Natarajan, Girija
    [J]. ACTA PAEDIATRICA, 2012, 101 (04) : E147 - E150
  • [10] ACHIEVEMENT OF PROPHYLACTIC ANTI-XA LEVELS IN TRAUMA PATIENTS RECEIVING ENOXAPARIN
    Meadows, Evan
    Partlow, Karen
    Rubertus, Matthew
    Quick, Valerie
    Davis, John
    Flannagan, Molly
    Griffin, Mary Lewis
    [J]. CRITICAL CARE MEDICINE, 2024, 52